Stay updated on DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial
Sign up to get notified when there's something new on the DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial page.

Latest updates to the DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.8%
- Check18 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check25 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check32 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check61 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check75 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed information about a Phase II clinical trial for a cancer vaccine and the addition of collaborators and a new revision number. The core content regarding the study's purpose and methodology has been largely deleted.SummaryDifference41%
Stay in the know with updates to DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DC/Myeloma Fusion+Nivolumab in Relapsed MM Clinical Trial page.